TRAF6在卵巢癌组织中的表达及临床意义

Expression of TRAF6 and its correlation with clinicopathologic characteristics in ovarian carcinomas

目的:探讨肿瘤坏死因子受体相关因子6(TRAF6)在卵巢癌及癌旁正常卵巢组织中的表达与临床意义。方法:收集2001年8月至2009年12月在我院接受手术治疗的102例卵巢癌患者的肿瘤标本及相对应的癌旁正常卵巢组织标本,所有肿瘤组织均经术后病理学检测结果证实,通过免疫组织化学方法检测TRAF6蛋白在卵巢癌及癌旁正常组织中的表达,并探讨TRAF6的表达量与临床病理特征和预后的相关性。结果:卵巢癌组织中TRAF6的阳性表达率为68.6%,显著高于癌旁正常卵巢组织中的20.5%(P<0.05);进一步研究发现,TRAF6的表达量与卵巢癌患者的年龄、肿瘤大小、有无腹水、组织学类型和病理分级无关(P>0.05),与患者有无淋巴结转移及临床分期相关(P<0.05);TRAF6阳性表达的患者五年生存率显著低于阴性表达的患者(P<0.001)。结论:TRAF6在卵巢癌组织中的表达显著降低,其可能在卵巢癌的发生、发展和侵袭中发挥重要作用。

Objective：To examine the expression of TRAF6 in ovarian carcinomas,discuss the relation between expression level and clinical characteristics of ovarian carcinomas and study the clinical significance. Methods： Specimens from 102 patients with ovarian carcinomas managed in our hospital between Augest 2001 and December 2009 were included in this study. Immunohistochemical staining was used to detect the expression of TRAF6 in ovarian carcinomas and normal tissues. All the specimens were confirmed by pathology for ovarian carcinomas and normal tissues by HE staining. Then,the correlation between the expression and clinical characteristics of patients was analyzed. Furthermore,survival analyses were performed according to the Kaplan-Meier method. Results： The positive expression rate of TRAF6 in ovarian carcinomas and normal tissues was 68. 6% and 20. 5%,respectively. TRAF6 expression was significantly associated with tumor stage and distant metastasis（ P 〈0. 05）. According to the survival analysis of 102 ovarian carcinomas patients,cases in the TRAF6 low-expression group showed poorer overall survival rate when compared with low-expression group（ P 〈0. 001）. Conclusion： These results indicate that the expression of TRAF6 was closely related with in the progression of ovarian carcinomas and may have clinical utility in the prediction of prognosis of ovarian carcinomas.